| 产品描述： | 1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity |
| 靶点： |
TLR7 |
| 体外研究： |
1V209 (0.1-10 μM) treatment significantly stimulates TNFα production in RAW246.7 cells. 1V209 (18 hours) treatment increases IL-6 production comparain bone marrow derived dendritic cells |
| 体内研究： |
The intravenous (IV) administration of the formulation to mice bearing 4T1 breast cancer tumors results in nanoparticle accumulation in tumors, reduction in primary tumor growth, and inhibition of lung metastases, as compared to saline-treated animals. Mice administered 1V209 experience significantly increases plasma levels of proinflammatory cytokines IL-6, IP-10, and MCP-1 at 2 h following IV administration |
| 参考文献： |
1. Battistella C, et al. Delivery of Immunotherapeutic Nanoparticles to Tumors via Enzyme-Directed Assembly. Adv Healthc Mater. 2019 Dec;8(23):e1901105. 2. Shinchi H, et al. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. Bioconjug Chem. 2015 Aug 19;26(8):1713-23. |
| 溶解性： |
Soluble in DMSO |
| 保存条件： |
-80℃（运输条件：冰袋低温运输） |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.783 ml |
13.914 ml |
27.829 ml |
| 5 mM |
0.557 ml |
2.783 ml |
5.566 ml |
| 10 mM |
0.278 ml |
1.391 ml |
2.783 ml |
| 50 mM |
0.056 ml |
0.278 ml |
0.557 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京